Long‐term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the
DEPICT
‐2 study): 52‐week results from a randomized controlled trial
Diabetes, Obesity and Metabolism（2020）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要